Factors influencing prescribing the first add-on disease-modifying antirheumatic drugs in patients initiating methotrexate for rheumatoid arthritis.

Huang, Yinan; Chatterjee, Satabdi; Agarwal, Sandeep K; Chen, Hua; Johnson, Michael L; Aparasu, Rajender R

Huang, Yinan; Chatterjee, Satabdi; Agarwal, Sandeep K; Chen, Hua; Johnson, Michael L; Aparasu, Rajender R.

Afiliação

Huang Y; Department of Pharmacy Administration, University of Mississippi, Oxford, MS, United States of America.
Chatterjee S; Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX, United States of America.
Agarwal SK; Section of Immunology, Allergy & Rheumatology, Department of Medicine, Baylor College of Medicine, Houston, TX, United States of America.
Chen H; Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX, United States of America.
Johnson ML; Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX, United States of America.
Aparasu RR; Department of Pharmaceutical Health Outcomes and Policy, College of Pharmacy, University of Houston, TX, United States of America.

Explor Res Clin Soc Pharm ; 11: 100296, 2023 Sep.

Article em En | MEDLINE | ID: mdl-37521021

Palavras-chave

Biological disease-modifying antirheumatic drugs; Combination therapy; Methotrexate; Rheumatoid arthritis; Tumor necrosis factor inhibitor biologics

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Explor Res Clin Soc Pharm Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google